Sage Group PLC closed 13.27% short of its 52-week high of £13.49, which the company achieved on February 6th.

Inc. ("Sage" or "the Company") (NASDAQ:SAGE). Investors who purchased Sage securities prior to April 12, 2021, and continue to hold to the present, are encouraged to obtain additional information and ...

Owner Rana Hamadani spent around $1 million to acquire and outfit the new space, which adds to her other location in ...

recent buyout offer for the company has passed. BofA withdrew its rating on SAGE in January after the depression drug developer said that Biogen (NASDAQ:BIIB) agreed to buy all the outstanding ...

US Bancorp DE raised its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) by 22.3% during the fourth quarter, ...

Sage Grey Finance Limited, a leading financial institution committed to creating impact through lending, investments, fund management and strategic advisory services, and its sister company, Sage Grey ...

March 21st, 2025, New York City – Jones, a leading vertical AI solution for insurance verification in construction and real estate, has announced today its integration with Sage Intacct, a leading ...

Financial institution Sage Grey Finance Limited and its sister company, Sage Grey Technologies, have recommitted to the provision of impact-driven solutions for businesses.This commitment was made at ...

Bank of America started coverage on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a report released on Tuesday. The brokerage issued an underperform rating and a $5.00 target price on the ...

Dr. Gault joined Sage Therapeutics in November 2022 and has led the Company’s product pipeline through all stages of development. Mike Quirk, Chief Scientific Officer, will assume key ...

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ...